Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

PURPOSE: Following promising responses to the DNA methyltransferase (DNMT) inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) combined with tetrahydrouridine (THU) in phase 1 testing, we initiated a non-randomized phase 2 study to assess response to this combination in patients with advanced solid tumor ty...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Coyne, Geraldine O.’Sullivan, Wang, Lihua, Zlott, Jennifer, Juwara, Lamin, Covey, Joseph M., Beumer, Jan H., Cristea, Mihaela C., Newman, Edward M., Koehler, Stephen, Nieva, Jorge J., Garcia, Agustin A., Gandara, David R., Miller, Brandon, Khin, Sonny, Miller, Sarah B., Steinberg, Seth M., Rubinstein, Larry, Parchment, Ralph E., Kinders, Robert J., Piekarz, Richard L., Kummar, Shivaani, Chen, Alice P., Doroshow, James H.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7188725/
https://ncbi.nlm.nih.gov/pubmed/32314030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04073-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados